YU30902A - Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju - Google Patents

Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju

Info

Publication number
YU30902A
YU30902A YU30902A YUP30902A YU30902A YU 30902 A YU30902 A YU 30902A YU 30902 A YU30902 A YU 30902A YU P30902 A YUP30902 A YU P30902A YU 30902 A YU30902 A YU 30902A
Authority
YU
Yugoslavia
Prior art keywords
compounds
production
cyclopropanes
novel
medicaments containing
Prior art date
Application number
YU30902A
Other languages
English (en)
Inventor
Wolfgang Eberlein
Wolfhard Engel
Klaus Rudolf
Henri Doods
Gerhard Hallermayer
Eckhart Bauer
Original Assignee
Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh. & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Publication of YU30902A publication Critical patent/YU30902A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Pronalazak se odnosi na jedinjenja opšte formule (I), u kojoj su R i R1 definisanl kao u zahtevu (1), na njihiove tautomere, njihove dijastereomere, njihove enantiomere, njihove smeše i njihove soli, naročito njihove fiziološki podnošljive soli, sa neorganskim ili organskim kiselinama ili bazama, koja imaju dragocena farmakološka svoistva, naročito CGRP-antagonistička svojstva, na lekove koji sadrže ova jedinjenja, na njihovu primenu i na postupak za njihovo pripremanje.[The invention relates to compounds of the general formula (I), in which R and R1 are defined as in claim 1. The invention also relates to their tautomers, diastereomers and enantiomers, to mixtures thereof and to their salts, especially to their physiologically acceptable salts with inorganic or organic acids or bases. The inventive compounds have valuable pharmacological properties, including CGRP antagonist properties. The invention further relates to medicaments that contain said compounds, to the use and the production thereof.
YU30902A 1999-10-29 2000-10-21 Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju YU30902A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19952147A DE19952147A1 (de) 1999-10-29 1999-10-29 Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
YU30902A true YU30902A (sh) 2005-07-19

Family

ID=7927315

Family Applications (1)

Application Number Title Priority Date Filing Date
YU30902A YU30902A (sh) 1999-10-29 2000-10-21 Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju

Country Status (26)

Country Link
US (2) US20030139417A1 (sh)
EP (1) EP1228059B1 (sh)
JP (1) JP3869721B2 (sh)
KR (1) KR20020047290A (sh)
CN (1) CN1177844C (sh)
AT (1) ATE301117T1 (sh)
AU (1) AU781856B2 (sh)
BG (1) BG106638A (sh)
BR (1) BR0015147A (sh)
CA (1) CA2387134C (sh)
CZ (1) CZ20021812A3 (sh)
DE (2) DE19952147A1 (sh)
EA (1) EA005137B1 (sh)
EE (1) EE200200220A (sh)
HR (1) HRP20020373A2 (sh)
HU (1) HUP0203496A3 (sh)
IL (1) IL148975A0 (sh)
MX (1) MXPA02004119A (sh)
NO (1) NO20021799L (sh)
NZ (1) NZ518698A (sh)
PL (1) PL354715A1 (sh)
SK (1) SK7282002A3 (sh)
TR (1) TR200201168T2 (sh)
WO (1) WO2001032648A1 (sh)
YU (1) YU30902A (sh)
ZA (1) ZA200203256B (sh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DK1539766T3 (en) * 2002-06-05 2017-04-03 Bristol Myers Squibb Co CALCITONIN GEN-RELATED PEPTIDE RECEPTOR ANTAGONISTS
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
CA2549330A1 (en) 2003-12-05 2005-07-21 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
ATE537153T1 (de) * 2004-09-09 2011-12-15 Merck Sharp & Dohme Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
WO2007061677A2 (en) * 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam aryl cgrp receptor antagonists
WO2009034029A2 (de) * 2007-09-07 2009-03-19 Boehringer Ingelheim International Gmbh 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
US8450327B2 (en) 2007-10-18 2013-05-28 Boehringer Ingelheim International Gmbh CGRP antagonists
CA2705405A1 (en) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds
US9315449B2 (en) * 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
US9822058B2 (en) * 2012-04-05 2017-11-21 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
ES2754473T3 (es) 2013-09-26 2020-04-17 Chdi Foundation Inc Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas, y método de uso de los mismos
EP3049077A4 (en) 2013-09-26 2017-02-15 CHDI Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2019040859A (ja) * 2017-08-22 2019-03-14 株式会社エンプラス 発光装置、面光源装置および光束制御部材
CN114957145B (zh) * 2022-04-14 2023-07-18 浙江师范大学 一种1,2,4-苯并三嗪衍生物及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655667A (en) * 1968-04-04 1972-04-11 Smith Kline French Lab 1-(2-benzoylcyclopropylmethyl)-4-phenylpiperazines
US3873707A (en) * 1972-10-02 1975-03-25 Robins Co Inc A H 1-Cyclopropyl-3-mono-(and 2,3-di) substituted-1-propanones in compositions and method for treating pain
FR2729855A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
HUP9901652A3 (en) 1995-12-15 2000-04-28 Novo Nordisk As Use of piperidine-carboxylic acid derivatives for producing pharmaceutical compositions suitable for reducing blood glucose
EP0934068A1 (en) * 1996-09-09 1999-08-11 Smithkline Beecham Corporation Compounds and methods
AU721035C (en) * 1996-09-10 2004-09-02 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
JP2002508754A (ja) 1997-05-22 2002-03-19 ジー ディ サール アンド カンパニ ｐ３８キナーゼ阻害剤としての置換基を有するピラゾール類
EP1071679A1 (en) * 1998-03-17 2001-01-31 Novo Nordisk A/S Novel heterocyclic compounds
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EE200100502A (et) * 1999-03-26 2002-12-16 Astrazeneca Ab Ühendid
DE19937304C2 (de) 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
US6696418B1 (en) * 1999-09-01 2004-02-24 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
TWI227231B (en) * 2000-07-12 2005-02-01 Novartis Ag 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3
AU2002223968A1 (en) * 2000-12-21 2002-07-01 Warner Lambert Company Llc Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
EP1441728A2 (en) * 2001-11-01 2004-08-04 Vertex Pharmaceuticals Incorporated Modulators of the cholesterol biosynthetic pathway
US6977265B2 (en) * 2001-11-30 2005-12-20 Roche Palo Alto Llc Piperidine CCR-3 receptor antagonists
US7026312B2 (en) * 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof

Also Published As

Publication number Publication date
AU781856B2 (en) 2005-06-16
BG106638A (bg) 2003-01-31
MXPA02004119A (es) 2003-10-06
ATE301117T1 (de) 2005-08-15
TR200201168T2 (tr) 2002-08-21
EP1228059A1 (de) 2002-08-07
HUP0203496A3 (en) 2004-01-28
US7407963B2 (en) 2008-08-05
CA2387134C (en) 2008-07-08
BR0015147A (pt) 2002-07-16
CN1387526A (zh) 2002-12-25
CA2387134A1 (en) 2001-05-10
CZ20021812A3 (cs) 2002-08-14
AU7921300A (en) 2001-05-14
NO20021799D0 (no) 2002-04-17
CN1177844C (zh) 2004-12-01
US20050267137A1 (en) 2005-12-01
EE200200220A (et) 2003-06-16
PL354715A1 (en) 2004-02-09
SK7282002A3 (en) 2002-11-06
US20030139417A1 (en) 2003-07-24
JP3869721B2 (ja) 2007-01-17
WO2001032648A1 (de) 2001-05-10
EA005137B1 (ru) 2004-12-30
DE50010886D1 (de) 2005-09-08
EP1228059B1 (de) 2005-08-03
NZ518698A (en) 2004-12-24
HUP0203496A2 (hu) 2003-02-28
IL148975A0 (en) 2002-11-10
DE19952147A1 (de) 2001-05-03
JP2003513087A (ja) 2003-04-08
HRP20020373A2 (en) 2003-10-31
KR20020047290A (ko) 2002-06-21
EA200200447A1 (ru) 2002-10-31
ZA200203256B (en) 2003-04-10
NO20021799L (no) 2002-04-17
HK1051858A1 (en) 2003-08-22

Similar Documents

Publication Publication Date Title
MXPA05004188A (es) Antagonistas de cgrp elegidos, procedimiento para su preparacion, asi como su empleo como medicamentos.
TW200602338A (en) Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
CA2387134A1 (en) Cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof
WO2009065919A3 (de) Organische verbindungen
TW200504032A (en) New carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions
WO2009065920A3 (de) Verbindungen
YU50002A (sh) Supstituisani piperidini, lekovi koji sadrže ova jedinjenja i postupci za njihovu proizvodnju
MX9803954A (es) Derivados de aminoacidos, composiciones farmaceuticas que contienen estos compuestos y procesos para prepararlos.
TW200504067A (en) New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
ES2139760T3 (es) Nuevas lactamas sustituidas con 4-piperidinilo con propiedades antagonistas del receptor de neurokinina 2 en el tratamiento del asma.
CA2337825A1 (en) Disubstituted bicyclic heterocycles, the preparation thereof and their use as pharmaceutical compositions
TW200603799A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
ATE413388T1 (de) Muskarin antagonisten
MX2010003849A (es) Antagonistas de cgrp.
NO20001483L (no) Nye NPY-agonister
WO2004112704A3 (en) Substituted piperidine compounds and methods of their use
FI973283A0 (fi) 5-(4-substituoitu piperidinyyli-1)-3-aryyli-valeriaanahappojohdannaisia takykiniinireseptoriantagonisteina
DK0733051T3 (da) Bicykliske, heterocykliske forbindelser som neurokinin A-antagonister
WO2003066594A3 (de) 3-alkanoylamino-propionsäure-derivate als inhibitoren des integrins avss6
WO1999062893A3 (de) Neue neurokininantagonisten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
TW200740795A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
TW200606153A (en) Process for producing pyridine derivatives of Nk-1 receptor antagonist
NO934760L (no) Arylsubstituerte heterosykliske forbindelser